Investigational New Drugs
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.4 | Q2 | 60.1% | 0.816 | Q2 | 77.9% |
| 2024 | 2.7 | Q2 | 53.8% | 1.074 | Q1 | 86.0% |
| 2023 | 3.0 | Q2 | 62.5% | 1.086 | Q1 | 87.5% |
| 2022 | 3.4 | Q2 | 62.5% | 0.943 | Q1 | 84.9% |
| 2021 | 3.7 | Q2 | 62.4% | 0.965 | Q1 | 85.8% |
| 2020 | — | — | 1.254 | Q1 | 89.7% | |
| 2019 | — | — | 1.493 | Q1 | 92.6% | |
| 2018 | — | — | 1.135 | Q1 | 86.9% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1573-0646
ISSN
0167-6997
country
UScoverage
1983-2026